Nov-11-20 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$4
Sep-18-20 Initiated
B. Riley FBR
Buy
$5
Feb-10-20 Initiated
SVB Leerink
Outperform
$6
Dec-10-19 Resumed
Cantor Fitzgerald
Neutral
$2 → $4
Aug-15-19 Downgrade
Maxim Group
Buy → Hold
Aug-12-19 Downgrade
Cantor Fitzgerald
Overweight → Neutral
$29 → $2
Jul-26-19 Downgrade
Mizuho
Buy → Neutral
$17 → $4
Jun-27-19 Initiated
Mizuho
Buy
Oct-12-18 Initiated
Mizuho
Buy
$17
Jun-05-18 Initiated
Seaport Global Securities
Buy
$29
Nov-08-17 Initiated
SunTrust
Buy
$26
Oct-16-17 Reiterated
H.C. Wainwright
Buy
$20 → $30
Oct-11-17 Reiterated
Cantor Fitzgerald
Overweight
$21 → $34
Oct-10-17 Initiated
Citigroup
Buy
$32
Oct-05-17 Reiterated
Maxim Group
Buy
$17 → $35
Sep-15-17 Initiated
RBC Capital Mkts
Outperform
$23
Jul-18-17 Reiterated
Maxim Group
Buy
$14 → $17
Jun-22-17 Resumed
Jefferies
Buy
$22
Jan-06-17 Initiated
Jefferies
Buy
Sep-29-16 Reiterated
Maxim Group
Buy
$8 → $14
Feb-25-21 11:33AM
Feb-22-21 07:30AM
Feb-12-21 11:36AM
Feb-02-21 07:30AM
Jan-25-21 07:30AM
Jan-12-21 08:50AM
Dec-21-20 12:20PM
Dec-14-20 09:44PM
Dec-01-20 10:06AM
09:09AM
Nov-27-20 08:25AM
Nov-24-20 03:10PM
03:08PM
03:07PM
Nov-18-20 11:24AM
Nov-17-20 01:16PM
Nov-12-20 05:21AM
Nov-09-20 05:55PM
04:05PM
Oct-27-20 06:30AM
Oct-14-20 10:58PM
Oct-06-20 04:01PM
Sep-28-20 09:27AM
Sep-18-20 11:08AM
09:31AM
Sep-08-20 04:05PM
Sep-01-20 06:29AM
Aug-17-20 07:00AM
Aug-10-20 04:01PM
Aug-04-20 11:36AM
Jul-10-20 07:30AM
Jul-09-20 09:10AM
07:30AM
Jul-08-20 07:30AM
Jul-03-20 07:48AM
Jun-23-20 11:59AM
Jun-18-20 07:30AM
Jun-17-20 07:30AM
Jun-08-20 09:11AM Thomson Reuters StreetEvents
May-28-20 11:30AM
08:30AM
May-08-20 12:58PM
May-07-20 01:59PM
May-06-20 04:14PM
Apr-29-20 11:08AM
Apr-21-20 04:04PM
08:00AM
Apr-20-20 08:43AM
06:06AM
Apr-17-20 07:00AM
Apr-06-20 09:16AM
Apr-05-20 04:12AM Thomson Reuters StreetEvents
Mar-27-20 06:19PM
Mar-23-20 12:00PM
Mar-17-20 07:30AM
Mar-16-20 04:20PM
Feb-26-20 08:00AM
Feb-21-20 08:45AM
Feb-12-20 02:15PM
Jan-21-20 08:00AM
Jan-15-20 09:33AM
Jan-13-20 09:00AM
Jan-02-20 12:12PM
11:55AM
10:28AM
04:52AM
Dec-31-19 12:30PM
12:00PM
Dec-27-19 08:30PM
06:00PM
Dec-24-19 02:20PM
01:30PM
01:01PM
Dec-20-19 06:20PM
10:44AM
10:22AM
10:00AM
09:24AM
Dec-19-19 05:20PM
05:00PM
01:03PM
Dec-18-19 03:59PM
Dec-17-19 02:25PM
Dec-16-19 07:10PM
10:51AM
10:22AM
Dec-15-19 10:00AM
Dec-14-19 09:36AM
Dec-13-19 04:30PM
12:03PM
10:00AM
Dec-12-19 01:30PM
10:00AM
09:00AM
Dec-11-19 05:17PM
02:25PM
09:48AM
Dec-09-19 05:45PM
01:06PM
10:20AM
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mann Paul Elliot Director Feb 19 Option Exercise 1.28 45,566 58,324 45,566 Feb 23 04:14 PM Wider Todd Director Feb 19 Sale 2.39 251,625 601,057 25,000 Feb 23 04:05 PM Mann Paul Elliot Director Feb 19 Sale 2.38 45,566 108,502 0 Feb 23 04:14 PM Wider Todd Director Feb 18 Option Exercise 1.28 1,345 1,722 277,970 Feb 19 04:05 PM Wider Todd Director Feb 18 Sale 2.43 1,345 3,273 276,625 Feb 19 04:05 PM Wider Todd Director Feb 17 Option Exercise 1.28 320,000 409,600 596,625 Feb 19 04:05 PM Wider Todd Director Feb 17 Sale 2.34 320,000 749,792 276,625 Feb 19 04:05 PM Mann Paul Elliot Director Feb 17 Sale 2.34 132,664 310,168 0 Feb 19 04:05 PM SCO CAPITAL PARTNERS LLC Director Feb 16 Sale 2.97 120,000 356,808 11,239,292 Feb 18 04:05 PM SCO CAPITAL PARTNERS LLC Director Feb 08 Sale 3.01 240,000 722,832 11,359,292 Feb 10 07:42 PM SCO CAPITAL PARTNERS LLC Director Jan 19 Sale 2.08 207,117 431,218 11,599,292 Jan 19 06:48 PM SCO CAPITAL PARTNERS LLC Director Jan 15 Sale 2.02 81,283 164,086 11,806,409 Jan 19 06:48 PM SCO CAPITAL PARTNERS LLC Director Jan 14 Sale 2.00 31,600 63,213 11,887,692 Jan 19 06:48 PM Wider Todd Director Jan 04 Sale 1.54 33,876 52,064 276,625 Jan 05 07:09 PM Mann Paul Elliot Director Jan 04 Sale 1.54 30,488 46,891 132,664 Jan 05 07:07 PM Mann Paul Elliot Director Dec 18 Sale 1.59 17,079 27,099 772,907 Dec 21 06:16 PM Wider Todd Director Dec 02 Sale 1.49 33,876 50,546 920,256 Dec 02 04:26 PM Mann Paul Elliot Director Dec 02 Sale 1.49 30,488 45,369 789,986 Dec 02 04:25 PM Wider Todd Director Nov 23 Sale 1.33 17,969 23,981 954,132 Nov 24 06:46 PM Mann Paul Elliot Director Nov 02 Sale 1.04 30,488 31,589 820,474 Nov 06 04:54 PM Wider Todd Director Nov 02 Sale 1.04 33,876 35,106 972,101 Nov 06 04:55 PM SCO CAPITAL PARTNERS LLC Director Sep 15 Sale 2.00 1,989 3,981 11,919,292 Sep 17 04:05 PM SCO CAPITAL PARTNERS LLC Director Sep 11 Sale 2.01 4,600 9,244 11,921,281 Sep 14 08:35 PM SCO CAPITAL PARTNERS LLC Director Sep 10 Sale 2.08 73,411 152,482 11,925,881 Sep 14 08:35 PM SCO CAPITAL PARTNERS LLC 10% Owner Aug 17 Sale 2.85 80,000 228,312 11,999,292 Aug 19 04:05 PM CARR EDWARD Chief Accounting Officer Mar 19 Sale 1.81 6,446 11,667 13,554 Mar 20 04:14 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite